RESMED INC RMD
We are a global leader in digital health and cloud-connected medical devices. We design innovative technology to empower people to live happier, healthier lives. Our artificial intelligence, or AI, powered digital health solutions, cloud-connected devices and intelligent software are designed to make home healthcare more personalized, accessible and effective. By enabling better care, our products improve quality of life, reduce the impact of chronic disease, and lower costs for consumers and healthcare systems.
Following our formation in 1989, we commercialized a continuous positive airway pressure, or CPAP, treatment for obstructive sleep apnea, or OSA, which was the first successful non-invasive treatment for OSA. CPAP systems deliver pressurized air, typically through a mask, to prevent collapse of the upper airway during sleep. Since the development of CPAP, we have expanded our business by developing or acquiring a number of innovative products and solutions for a broad range of sleep and related breathing health disorders including technologies to be applied in medical and consumer products, life support and ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, and dental devices. In addition, we are a leading provider of cloud-based health applications, software and devices designed to provide connected care, enabling clinicians to manage more patients efficiently and effectively, as well as enabling and encouraging patients' long-term adherence to and satisfaction with their therapy.
Valuation FY2026 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $5.65B | $5.15B | $4.69B | $4.22B | $3.58B | $3.20B | $2.96B | $2.61B | $2.34B | $2.07B |
| Cost of revenue | $2.20B | $2.09B | $2.03B | $1.87B | $1.55B | $1.36B | $1.24B | $1.11B | $1.01B | $865.0M |
| Gross profit | $3.45B | $3.05B | $2.66B | $2.36B | $2.02B | $1.84B | $1.72B | $1.49B | $1.33B | $1.20B |
| R&D | $378.3M | $331.3M | $307.5M | $287.6M | $253.6M | $225.3M | $201.9M | $180.7M | $155.1M | $144.5M |
| SG&A | $1.12B | $993.0M | $917.1M | $874.0M | $737.5M | $670.4M | $676.7M | $645.0M | $600.4M | $554.0M |
| Total operating expenses | $1.57B | $1.37B | $1.34B | $1.22B | $1.02B | $935.4M | $908.1M | $914.8M | $793.1M | $775.9M |
| Operating income | $1.89B | $1.69B | $1.32B | $1.13B | $1.00B | $903.7M | $809.7M | $579.3M | $541.8M | $425.8M |
| Interest expense | — | — | — | $47.4M | $22.3M | $23.6M | $39.4M | $36.2M | $28.4M | $28.2M |
| Pre-tax income | $1.92B | $1.68B | $1.26B | $1.10B | $960.5M | $883.7M | $733.1M | $518.8M | $521.3M | $418.7M |
| Income tax | $396.1M | $276.8M | $243.8M | $204.1M | $181.0M | $409.2M | $111.4M | $114.3M | $205.7M | $76.5M |
| Net income | $1.52B | $1.40B | $1.02B | $897.6M | $779.4M | $474.5M | $621.7M | $404.6M | $315.6M | $342.3M |
| EPS, basic | 10.47 | 9.55 | 6.94 | 6.12 | 5.34 | 3.27 | 4.31 | 2.83 | 2.21 | 2.42 |
| EPS, diluted | 10.43 | 9.51 | 6.92 | 6.09 | 5.30 | 3.24 | 4.27 | 2.80 | 2.19 | 2.40 |
| Shares, diluted (wtd. avg.) | $146.1M | $147.3M | $147.6M | $147.5M | $147.0M | $146.5M | $145.7M | $144.5M | $144.0M | $142.5M |
Balance sheet
| Fiscal year | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $1.47B | $1.21B | $238.4M | $227.9M | $273.7M | $295.3M | $463.2M | $147.1M | $188.7M | $821.9M |
| Receivables | $1.04B | $939.5M | $837.3M | $704.9M | $576.0M | $614.3M | $474.6M | $528.5M | $483.7M | $450.5M |
| Inventory | $945.8M | $927.7M | $822.2M | $998.0M | $743.9M | $457.0M | $416.9M | $349.6M | $268.7M | $268.3M |
| Total current assets | $4.32B | $3.51B | $2.36B | $2.37B | $1.93B | $1.57B | $1.52B | $1.15B | $1.07B | $1.64B |
| Property, plant and equipment | $581.8M | $550.8M | $548.0M | $537.9M | $498.2M | $463.5M | $417.3M | $387.5M | $386.6M | $394.2M |
| Goodwill | $2.91B | $3.05B | $2.84B | $2.77B | $1.94B | $1.93B | $1.89B | $1.86B | $1.07B | $1.06B |
| Other intangibles | $452.7M | $464.9M | $485.9M | $552.3M | $345.9M | $392.6M | $448.2M | $522.0M | $215.2M | $261.8M |
| Total assets | $8.97B | $8.17B | $6.87B | $6.75B | $5.10B | $4.73B | $4.59B | $4.11B | $3.06B | $3.47B |
| Accounts payable | $308.9M | $278.2M | $237.7M | $150.8M | $159.2M | $138.0M | $135.8M | $115.7M | $92.7M | $92.8M |
| Short-term debt | $259.9M | $9.9M | $9.9M | $9.9M | $9.9M | $12.0M | $12.0M | $12.0M | $11.5M | — |
| Total current liabilities | $1.40B | $1.02B | $910.7M | $758.5M | $689.3M | $911.8M | $602.8M | $556.0M | $511.2M | $360.1M |
| Long-term debt | $399.4M | $658.4M | $697.3M | $1.43B | $765.3M | $643.4M | $1.16B | $1.26B | $270.0M | $1.08B |
| Total liabilities | $2.38B | $2.21B | $2.01B | $2.62B | $1.74B | $1.84B | $2.09B | $2.04B | $1.00B | $1.51B |
| Retained earnings | $7.26B | $6.08B | $4.99B | $4.25B | $3.61B | $3.08B | $2.83B | $2.44B | $2.43B | $2.32B |
| Total equity | $6.59B | $5.97B | $4.86B | $4.13B | $3.36B | $2.89B | $2.50B | $2.07B | $2.06B | $1.96B |
Cash flow
| Fiscal year | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $1.81B | $1.75B | $1.40B | $693.3M | $351.1M | $736.7M | $802.3M | $459.1M | $505.0M | $414.1M |
| Depreciation and amortisation | $201.3M | $198.5M | $176.9M | $165.2M | $159.6M | $156.8M | $154.8M | $150.8M | $120.0M | $112.2M |
| Stock-based compensation | $104.3M | $91.7M | $80.2M | $71.1M | $65.3M | $63.9M | $57.6M | $52.1M | $48.4M | $45.9M |
| Capital expenditure | $156.3M | $89.9M | $99.5M | $119.7M | $134.8M | $102.7M | $95.3M | $68.7M | $62.6M | $62.2M |
| Investing cash flow | -$545.2M | -$200.0M | -$269.8M | -$1.16B | -$229.9M | -$158.5M | -$179.9M | -$1.08B | -$101.8M | -$81.9M |
| Financing cash flow | -$1.01B | -$606.3M | -$1.12B | $422.9M | -$128.4M | -$764.6M | -$317.3M | $580.6M | -$1.03B | -$262.9M |
| Dividends paid | $349.7M | $310.9M | $282.3M | $258.3M | $245.3M | $226.7M | $225.1M | $211.7M | $199.5M | $186.3M |
| Buybacks | $700.0M | $300.0M | $150.0M | $0 | $0 | — | — | $22.8M | $53.8M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0000943819-26-000047.
Others in SIC 3841
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| SYK | STRYKER CORP | $116.27B | 36.1x | 11.2% |
| MMM | 3M CO | $86.93B | 28.1x | 1.5% |
| BSX | BOSTON SCIENTIFIC CORP | $69.27B | 24.6x | 19.9% |
| BDX | BECTON DICKINSON & CO | $50.32B | 31.7x | 8.2% |
| DXCM | DEXCOM INC | $33.17B | 42.1x | 15.6% |
| MDLN | Medline Inc. | $31.35B | — | 11.5% |
| WST | WEST PHARMACEUTICAL SERVICES INC | $23.93B | 50.1x | 6.3% |
| SOLV | Solventum Corp | $15.61B | 10.3x | 0.9% |